Enhanced EHR-workflow-integrated communications enable prescribers to act on lower-cost therapeutic alternatives, while reinforcing Scripta’s proven member-drivenEnhanced EHR-workflow-integrated communications enable prescribers to act on lower-cost therapeutic alternatives, while reinforcing Scripta’s proven member-driven

Scripta Insights Expands Clinically Governed Provider Engagement Within Its Rx Navigation Platform

2026/02/10 23:32
4 min read

Enhanced EHR-workflow-integrated communications enable prescribers to act on lower-cost therapeutic alternatives, while reinforcing Scripta’s proven member-driven savings model

BOSTON, Feb. 10, 2026 /PRNewswire/ — Scripta Insights, the doctor-driven, AI-powered pharmacy navigation company that guides self-insured employers, health plans, and their members to prescription savings, has strengthened its provider engagement capabilities through enhanced, secure EHR-workflow-integrated electronic fax communications.

The enhancement enables prescribing clinicians to review clinically equivalent, lower-cost alternatives and approve or decline recommended switches directly within their existing clinical workflows—supporting efficient alignment on potential savings opportunities, while preserving the physician’s clinical judgment and the member experience.

Unlike point solutions that focus on prescriber outreach alone, Scripta’s provider engagement capabilities operate as part of its broader Rx Navigation platform—connecting prescribers, members and plan sponsors through a single, clinically governed system designed to drive both immediate and sustained pharmacy savings.

When a savings opportunity is identified, Scripta delivers recommendations aligned to the employer’s benefit design and formulary directly to the provider, including pricing and therapeutic alternatives. Providers can then approve or decline the recommendation on the member’s behalf, reducing friction for patients and helping avoid prescription abandonment.

Scripta’s provider engagement model is governed by its independent Pharmacy & Therapeutics (P&T) Committee, composed of 30 actively practicing physicians and pharmacists representing 22 clinical specialties. The committee evaluates therapeutic alternatives based on clinical appropriateness, evidence and real-world practice considerations to ensure that recommendations reflect decisions a practicing clinician would reasonably make for their own patients.

This clinical governance model enables:

  • Evidence-based, clinically appropriate recommendations
  • Peer-to-peer physician credibility
  • Higher likelihood of provider adoption and sustained action

“At the end of a long day in the exam room, the last thing a physician wants is a message that simply says ‘change to this medication’ without context,” said Dr. Paul Bradley, Co-Founder and Chief Medical Officer of Scripta Insights. “Scripta’s enhanced provider engagement approach delivers the right information to clinicians at the right time, helping physicians have more informed, productive conversations with their patients—without disrupting how they already practice medicine.”

“Expanding clinically governed provider engagement scales a powerful lever we already use to help plan sponsors drive prescription savings,” said Eric Levin, CEO of Scripta Insights. “Across more than 100 employer and health plan clients, we see the strongest and most durable results when prescribers and members are both supported with clear, personalized guidance. Our Rx Navigation platform brings these capabilities together in a single, end-to-end solution that works within existing benefit designs and vendor ecosystems to help organizations drive meaningful and sustainable pharmacy savings.”

Across its client base, Scripta data shows:

  • Approximately 29 percent of all active members on prescriptions have at least one identified savings opportunity
  • Among active members with identified savings opportunities, 40 percent complete a medication switch that saves
  • Members save an average of $25 per month
  • 93 percent of medication switches driven by Scripta’s clinical recommendations remain in place after 12 months

Scripta’s Rx Navigation platform supports coordinated decision-making across members, prescribers and plan sponsors through tools including member-facing navigation, prescriber engagement, plan sponsor analytics and targeted incentive programs—working alongside any PBM and within a client’s existing benefit design.

Scripta operates as an independent, unbiased third party, delivering clinically governed recommendations, flexible integration and transparent reporting—designed to support plan sponsors in meeting their ERISA fiduciary responsibilities and aligned exclusively to employer and health plan goals.

About Scripta Insights
Scripta Insights is a venture-backed digital health company providing clinically governed pharmacy navigation solutions for self-insured employers, health plans and their members. Founded in 2019, the company’s platform was developed by physicians, pharmacists and data scientists to help stakeholders navigate the growing complexity of prescription benefits and medication decision-making.
For more information, visit www.scriptainsights.com and follow the company on LinkedIn.

Media Contact
Linda Krebs
LKPR, Inc. for Scripta Insights
[email protected]
646-824-5186

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/scripta-insights-expands-clinically-governed-provider-engagement-within-its-rx-navigation-platform-302683042.html

SOURCE Scripta Insights

Market Opportunity
The AI Prophecy Logo
The AI Prophecy Price(ACT)
$0.0137
$0.0137$0.0137
-4.66%
USD
The AI Prophecy (ACT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Fed Acts on Economic Signals with Rate Cut

Fed Acts on Economic Signals with Rate Cut

In a significant pivot, the Federal Reserve reduced its benchmark interest rate following a prolonged ten-month hiatus. This decision, reflecting a strategic response to the current economic climate, has captured attention across financial sectors, with both market participants and policymakers keenly evaluating its potential impact.Continue Reading:Fed Acts on Economic Signals with Rate Cut
Share
Coinstats2025/09/18 02:28
Ray Dalio Raises Alarms on Potential State Overreach with Digital Currencies

Ray Dalio Raises Alarms on Potential State Overreach with Digital Currencies

The post Ray Dalio Raises Alarms on Potential State Overreach with Digital Currencies appeared on BitcoinEthereumNews.com. Renowned for his keen perspectives on
Share
BitcoinEthereumNews2026/02/11 01:07
Breaking: CME Group Unveils Solana and XRP Options

Breaking: CME Group Unveils Solana and XRP Options

CME Group launches Solana and XRP options, expanding crypto offerings. SEC delays Solana and XRP ETF approvals, market awaits clarity. Strong institutional demand drives CME’s launch of crypto options contracts. In a bold move to broaden its cryptocurrency offerings, CME Group has officially launched options on Solana (SOL) and XRP futures. Available since October 13, 2025, these options will allow traders to hedge and manage exposure to two of the most widely traded digital assets in the market. The new contracts come in both full-size and micro-size formats, with expiration options available daily, monthly, and quarterly, providing flexibility for a diverse range of market participants. This expansion aligns with the rising demand for innovative products in the crypto space. Giovanni Vicioso, CME Group’s Global Head of Cryptocurrency Products, noted that the new options offer increased flexibility for traders, from institutions to active individual investors. The growing liquidity in Solana and XRP futures has made the introduction of these options a timely move to meet the needs of an expanding market. Also Read: Vitalik Buterin Reveals Ethereum’s Bold Plan to Stay Quantum-Secure and Simple! Rapid Growth in Solana and XRP Futures Trading CME Group’s decision to roll out options on Solana and XRP futures follows the substantial growth in these futures products. Since the launch of Solana futures in March 2025, more than 540,000 contracts, totaling $22.3 billion in notional value, have been traded. In August 2025, Solana futures set new records, with an average daily volume (ADV) of 9,000 contracts valued at $437.4 million. The average daily open interest (ADOI) hit 12,500 contracts, worth $895 million. Similarly, XRP futures, which launched in May 2025, have seen significant adoption, with over 370,000 contracts traded, totaling $16.2 billion. XRP futures also set records in August 2025, with an ADV of 6,600 contracts valued at $385 million and a record ADOI of 9,300 contracts, worth $942 million. Institutional Demand for Advanced Hedging Tools CME Group’s expansion into options is a direct response to growing institutional interest in sophisticated cryptocurrency products. Roman Makarov from Cumberland Options Trading at DRW highlighted the market demand for more varied crypto products, enabling more advanced risk management strategies. Joshua Lim from FalconX also noted that the new options products meet the increasing need for institutional hedging tools for assets like Solana and XRP, further cementing their role in the digital asset space. The launch of options on Solana and XRP futures marks another step toward the maturation of the cryptocurrency market, providing a broader range of tools for managing digital asset exposure. SEC’s Delay on Solana and XRP ETF Approvals While CME Group expands its offerings, the broader market is also watching the progress of Solana and XRP exchange-traded funds (ETFs). The U.S. Securities and Exchange Commission (SEC) has delayed its decisions on multiple crypto-related ETF filings, including those for Solana and XRP. Despite the delay, analysts anticipate approval may be on the horizon. This week, REX Shares and Osprey Funds are expected to launch an XRP ETF that will hold XRP directly and allocate at least 40% of its assets to other XRP-related ETFs. Despite the delays, some analysts believe that approval could come soon, fueling further interest in these assets. The delay by the SEC has left many crypto investors awaiting clarity, but approval of these ETFs could fuel further momentum in the Solana and XRP futures markets. Also Read: Tether CEO Breaks Silence on $117,000 Bitcoin Price – Market Reacts! The post Breaking: CME Group Unveils Solana and XRP Options appeared first on 36Crypto.
Share
Coinstats2025/09/18 02:35